Macrophages make a difference in cholestatic liver diseases - but how?

J Hepatol. 2023 Dec;79(6):1349-1351. doi: 10.1016/j.jhep.2023.09.022. Epub 2023 Oct 10.

Authors

Christy E Trussoni¹, Nicholas F LaRusso²

Affiliations

¹ Division of Gastroenterology and Hepatology and the Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, MN, USA.
² Division of Gastroenterology and Hepatology and the Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, MN, USA. Electronic address: larusso.nicholas@mayo.edu.

PMID: 37821021
DOI: 10.1016/j.jhep.2023.09.022

No abstract available

Keywords: ARID3A; Cholangiopathies; MERTK; biliary epithelial cell; efferocytosis; macrophages.

Publication types

Editorial
Comment

MeSH terms

Cholestasis*
Humans
Liver Diseases*
Macrophages
Phagocytosis
Receptor Protein-Tyrosine Kinases
c-Mer Tyrosine Kinase

Substances

Receptor Protein-Tyrosine Kinases
c-Mer Tyrosine Kinase